Published in Prostate on July 01, 2008
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med (2011) 1.18
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res (2012) 0.98
Non-invasive biomarker in prostate carcinoma: a novel approach. Indian J Clin Biochem (2013) 0.97
Cancer epigenetics: above and beyond. Toxicol Mech Methods (2011) 0.95
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther (2009) 0.94
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther (2013) 0.92
High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 0.89
High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma. J Transl Med (2012) 0.88
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. Int J Clin Exp Pathol (2014) 0.85
Pregnancy-induced chromatin remodeling in the breast of postmenopausal women. Int J Cancer (2012) 0.83
DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology (2009) 0.81
Design of small molecule epigenetic modulators. Bioorg Med Chem Lett (2013) 0.81
Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies. PLoS One (2013) 0.80
The effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines. Adv Biomed Res (2013) 0.79
Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5. Nucleic Acids Res (2017) 0.77
Effective Quenchers Are Required to Eliminate the Interference of Substrate: Cofactor Binding in the HAT Scintillation Proximity Assay. Assay Drug Dev Technol (2015) 0.77
Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines. Int J Prev Med (2013) 0.76
Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. Biochemistry (2016) 0.75
P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Oncotarget (2016) 0.75
Protective effect of α-lipoic acid against radiation-induced fibrosis in mice. Oncotarget (2016) 0.75
Effects of caffeine on cell viability and activity of histone deacetylase 1 and histone acetyltransferase in glioma cells. Ci Ji Yi Xue Za Zhi (2016) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 44.55
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 16.79
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell (2002) 12.28
CBP/p300 in cell growth, transformation, and development. Genes Dev (2000) 10.76
Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev (2000) 9.36
Role of CBP/P300 in nuclear receptor signalling. Nature (1996) 7.36
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell (1998) 6.73
Prostate cancer. N Engl J Med (2003) 5.91
Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell (1999) 5.23
p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol (1999) 4.88
Regulation of activity of the transcription factor GATA-1 by acetylation. Nature (1998) 4.68
CREB-binding protein and p300 in transcriptional regulation. J Biol Chem (2001) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Acetylation of general transcription factors by histone acetyltransferases. Curr Biol (1997) 4.22
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci U S A (1996) 3.43
Histologic grading of prostate cancer: a perspective. Hum Pathol (1992) 3.36
Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci U S A (1998) 3.13
HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J (1999) 3.10
Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell (1998) 3.09
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature (1998) 2.98
p300 and CBP: partners for life and death. J Cell Physiol (1999) 2.36
The development of common data elements for a multi-institute prostate cancer tissue bank: the Cooperative Prostate Cancer Tissue Resource (CPCTR) experience. BMC Cancer (2005) 2.35
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol (2000) 2.30
CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol (1999) 2.26
p300 gene alterations in colorectal and gastric carcinomas. Oncogene (1996) 2.01
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers. Clin Cancer Res (2004) 1.85
E2F family members are differentially regulated by reversible acetylation. J Biol Chem (2000) 1.77
The tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue Resource. BMC Bioinformatics (2004) 1.74
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol (2004) 1.61
Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res (2004) 1.56
Functional interaction between nucleosome assembly proteins and p300/CREB-binding protein family coactivators. Mol Cell Biol (2000) 1.55
Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res (2002) 1.53
p300 in prostate cancer proliferation and progression. Cancer Res (2003) 1.50
Where the cell cycle and histones meet. Genes Dev (2000) 1.49
CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene (2000) 1.44
p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res (2002) 1.36
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene (2000) 1.11
Acetylation of novel sites in the nucleosomal binding domain of chromosomal protein HMG-14 by p300 alters its interaction with nucleosomes. J Biol Chem (2000) 1.08
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer (2003) 0.98
Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem Suppl (2000) 0.97
A simple computer program for calculating PSA recurrence in prostate cancer patients. BMC Urol (2004) 0.94
Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev (2008) 0.94
Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl (1994) 0.91
Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate (2007) 0.88
Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer (1994) 0.82
The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol (1998) 0.80
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
A 61-million-person experiment in social influence and political mobilization. Nature (2012) 6.16
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med (2012) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Structural diversity in social contagion. Proc Natl Acad Sci U S A (2012) 2.28
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology (2013) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. J Infect Dis (2005) 2.23
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04
Template boundary definition in Tetrahymena telomerase. Genes Dev (2002) 1.96
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
RpoS controls the Vibrio cholerae mucosal escape response. PLoS Pathog (2006) 1.87
Roles for RNA in telomerase nucleotide and repeat addition processivity. Mol Cell (2003) 1.86
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Validation of the partin nomogram for prostate cancer in a national sample. J Urol (2010) 1.64
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol (2008) 1.63
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Causes of death after radical prostatectomy at a large tertiary center. J Urol (2012) 1.61
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate (2010) 1.60
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int (2010) 1.58
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology (2002) 1.56
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate (2008) 1.53
Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int (2013) 1.48
The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer. Cancer (2010) 1.48
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol (2010) 1.47
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol (2002) 1.47
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
A G protein/cAMP signal cascade is required for axonal convergence into olfactory glomeruli. Proc Natl Acad Sci U S A (2007) 1.46
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate (2013) 1.46
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res (2005) 1.46
Free prostate-specific antigen in serum is becoming more complex. Urology (2002) 1.46
Biomarkers for prostate cancer. Annu Rev Med (2009) 1.45
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology (2010) 1.44
Applying complexed prostate-specific antigen to clinical practice. Urology (2004) 1.44
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol (2002) 1.43
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate (2004) 1.43
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol (2006) 1.42
Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. BJU Int (2013) 1.42
A new formula for prostate cancer lymph node risk. Int J Radiat Oncol Biol Phys (2010) 1.42
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41
Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology (2002) 1.41
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? Urology (2008) 1.40